These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22343494)

  • 1. Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications.
    Collins L; Basaria S
    Asian J Androl; 2012 Mar; 14(2):222-5. PubMed ID: 22343494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care.
    Collins L; Mohammed N; Ahmad T; Basaria S
    J Endocrinol Invest; 2012 Mar; 35(3):332-9. PubMed ID: 22391014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
    Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.
    Saylor PJ; Smith MR
    J Natl Compr Canc Netw; 2010 Feb; 8(2):211-23. PubMed ID: 20141678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.
    Storer TW; Miciek R; Travison TG
    Asian J Androl; 2012 Mar; 14(2):204-21. PubMed ID: 22367184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
    Foulkes SJ; Daly RM; Fraser SF
    Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
    Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
    Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.
    Saylor PJ; Keating NL; Smith MR
    J Gen Intern Med; 2009 Nov; 24 Suppl 2(Suppl 2):S389-94. PubMed ID: 19838837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.